Last checked at 1 Apr 2019 17:44
Shield Therapeutics plc
("Shield" or the "Group")
Additional listing
London, UK, 1 April 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that it issued and allotted 268,196 Ordinary Shares of 1.5p each on 21 February 2019 following the exercise of options under the Shield Therapeutics plc 2016 Company Share Option Plan.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 5 April 2019. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
Following admission, the Company's issued share capital will comprise 116,694,047 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 116,694,047. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
- Ends -
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Carl Sterritt, Chief Executive Officer | +44 (0)20 7186 8500 |
Tim Watts, Chief Financial Officer |
|
|
|
Nominated Advisor and Broker |
|
Peel Hunt LLP |
|
James Steel/Dr Christopher Golden | +44 (0)20 7418 8900 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus / Helen Cresswell | +44 (0)7980 541 893 / +44 (0)7841 917 679 |
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.
1 - https://www.shieldtherapeutics.com/rns_news/positive-results-for-feraccru-in-aegis-h2h-study/